In patients with imatinib-resistant CML, drug resistance-mediating mutations outside the BCR-ABL fusion site have been identified (59) and specific T-cell responses against neoepitopes derived from these mutations have been demonstrated and were linked with clinical response (59). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.